Use of everolimus in liver transplantation

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 23

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Hepatol. Aug 18, 2017; 9(23): 990-1000
Published online Aug 18, 2017. doi: 10.4254/wjh.v9.i23.990

Table 3 Recommendation for everolimus use in liver transplantation recipients

Indication and regimen	Renoprotective benefit
	EVR in combination with CNI to allow CNI dose reduction
	Management of CNI neurotoxicity
	EVR allows temporary withdrawal of CNI till resolution of neurotoxicity
Patients	LT recipients with renal function > 60 mL/min
Patients	LT recipients proteinuria < 1 g/24 h
Timing	De novo therapy: Initiate EVR at 1 mo from transplant
	Maintenance therapy: Introduce EVR within 1 yr from transplant
	CNI neurotoxicity: Stop CNI and initiate EVR immediately

CNI: Calcineurin inhibitor; EVR: Everolimus; LT: Liver transplantation.

Citation: Yee ML, Tan HH. Use of everolimus in liver transplantation. World J Hepatol 2017; 9(23): 990-1000
URL: https://www.wjgnet.com/1948-5182/full/v9/i23/990.htm
DOI: https://dx.doi.org/10.4254/wjh.v9.i23.990

Yee ML, Tan HH. Use of everolimus in liver transplantation. World J Hepatol 2017; 9(23): 990-1000 [PMID: 28878864 DOI: 10.4254/wjh.v9.i23.990]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.